<DOC>
	<DOCNO>NCT02476123</DOCNO>
	<brief_summary>The purpose study characterize safety tolerability determine maximum tolerate dose ( MTD ) recommend fix dose combination Mogamulizumab Nivolumab subject locally advanced metastatic solid tumor .</brief_summary>
	<brief_title>Study Combination Therapy With Mogamulizumab ( KW-0761 ) Nivolumab ( ONO-4538/BMS-936558 ) Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subjects voluntarily sign dated Institutional Review Board approve inform consent form accordance regulatory institutional guideline . Subjects progress intolerant standard treatment regimen refuse standard treatment , adequate standard therapy exist . Subjects evaluable lesion per guideline Response Evaluation Criteria Solid Tumors ( RECIST ) version 1.1 . Subjects life expectancy &gt; 12 week . Subjects Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Potential childbearing female agree contraception breastfeeding . For male also agree contraception . Subjects adequate hematological , renal , hepatic respiratory function define . Must agree present archival tumor tissue sponsor willing undergo pretreatment biopsy . Histologically cytologically confirm locally advanced metastatic solid tumor . Female subject pregnant breastfeeding . Subjects uncontrolled significant intercurrent illness . Subjects known central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Subjects previously treat antiprogrammed death 1 ( PD1 ) , antiPDL1 , antiPDL2 , antiCD137 , antiCytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody antibody drug specifically target Tcell costimulation checkpoint pathway . Subjects previously treat Mogamulizumab . Subjects prior Grade â‰¥ 3 immunerelated adverse event ( irAE ) receive previous immunotherapy agent , unresolved irAE . Subjects history severe hypersensitivity reaction drug . Subjects receive chemotherapy , immunotherapy , biologic hormonal therapy , another investigational drug , radiation major surgery cancer treatment within 28 day 42 day ( nitrosourea mitomycin C ) prior Cycle 1 Day 1 . Subjects know active autoimmune disease syndrome . Subjects active inflammatory bowel disease , irritable bowel disease , celiac disease , serious GI chronic condition associate diarrhea .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>